Aclarion, Inc. (NASDAQ:ACON) Sees Significant Increase in Short Interest

Aclarion, Inc. (NASDAQ:ACON) was the target of a significant increase in short interest in December. As of December 31st, there was short interest totalling 1,810,000 shares, an increase of 47.2% from the December 15th total of 1,230,000 shares. Currently, 17.4% of the shares of the company are sold short. Based on an average daily trading volume, of 6,370,000 shares, the days-to-cover ratio is presently 0.3 days.

Aclarion Trading Down 12.3 %

Shares of Aclarion stock opened at $0.10 on Wednesday. The firm’s 50-day simple moving average is $0.16 and its 200-day simple moving average is $0.20. Aclarion has a twelve month low of $0.10 and a twelve month high of $3.85.

Wall Street Analyst Weigh In

Several research firms have commented on ACON. Maxim Group reaffirmed a “hold” rating on shares of Aclarion in a report on Friday, December 13th. Ascendiant Capital Markets cut their target price on Aclarion from $1.50 to $1.30 and set a “buy” rating for the company in a research note on Wednesday, November 27th.

Aclarion Company Profile

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software.